Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.06% | -72.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.06% | -72.07% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 2.06% | -72.07% | |||
| SG&A Expenses | 9.73% | -0.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.12% | -3.69% | |||
| Operating Income | -20.41% | -446.15% | |||
| Income Before Tax | -30.05% | -586.59% | |||
| Income Tax Expenses | 57.14% | -75.86% | |||
| Earnings from Continuing Operations | -30.05% | -587.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -417.44% | 88.40% | |||
| Net Income | -46.37% | -530.79% | |||
| EBIT | -20.41% | -446.15% | |||
| EBITDA | -21.16% | -385.79% | |||
| EPS Basic | -45.39% | -514.59% | |||
| Normalized Basic EPS | -35.81% | -542.18% | |||
| EPS Diluted | -45.92% | -523.64% | |||
| Normalized Diluted EPS | -35.81% | -554.17% | |||
| Average Basic Shares Outstanding | 0.67% | 3.92% | |||
| Average Diluted Shares Outstanding | 0.67% | 1.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||